The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The company quietly deprioritises AlphaMedix.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
RMC-5127 becomes the company’s fourth clinical project.
The line-up is revealed to include Merck & Co and J&J itself.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
